FDA to Evaluate BLA for Datopotamab Deruxtecan in Non-Small Cell Lung Cancer

The FDA set a Prescription Drug User Fee Act date during Q4 of 2024 for the biologics license application for datopotamab deruxtecan in patients with previously treated advanced nonsquamous non-small cell lung cancer.

Source link
#FDA #Evaluate #BLA #Datopotamab #Deruxtecan #NonSmall #Cell #Lung #Cancer